Antiplatelets Have Blockbuster Potential.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c27837) has announced the addition of Pipeline Insight: Antithrombotics - Anticoagulants Anticoagulants Drugs that suppress, delay, or prevent blood clots. Anticoagulants are used to treat embolisms. Mentioned in: Embolism, Heart Valve Replacement and Antiplatelets Have Blockbuster block·bust·er n. 1. Something, such as a film or book, that sustains widespread popularity and achieves enormous sales. 2. A high-explosive bomb used for demolition purposes. 3. Potential to their offering. It is estimated the total revenue generated from new antithrombotics in the seven major markets will reach approximately $10bn by 2015, with novel oral anticoagulants contributing over 70% to this volume. However, barriers to entry exist and developmental antithrombotics must pursue an aggressive development strategy to compete successfully with well-established gold-standard therapies. This report provides an assessment of the patient potential for developmental antithrombotics in the major thrombosis thrombosis (thrŏmbō`sĭs), obstruction of an artery or vein by a blood clot (thrombus). Arterial thrombosis is generally more serious because the supply of oxygen and nutrition to an area of the body is halted. indications over the period 2005-15. It gives an overview of the antithrombotic R&D pipeline with detailed information on the classes in development. Commercial analysis of key compounds in development in terms of their ability to satisfy unmet un·met adj. Not satisfied or fulfilled: unmet demands. needs, supported by the views of key opinion leaders is provided together with sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for key late-stage developmental antithrombotics in the seven major markets to 2015. After the demise of AstraZeneca's anticoagulant anticoagulant (ăn'tēkōăg`yələnt), any of several substances that inhibit blood clot formation (see blood clotting). Exanta, Boehringer Ingelheims BIBR-1048 and Bayer's BAY-597939 are next in line with a chance to switch warfarin-treated patients and grow the market by recruiting the previously untreated population. Prasugrel and cangrelor are the most promising developmental antiplatelets with the potential to successfully challenge established drugs such as clopidogrel and GPIIb/IIIa blockers. Developmental thrombolytics hold little commercial promise because of established competitors, niche-focused launch strategies, and the overall decline of the thrombolytics market, driven by the increase in cardiovascular surgery cardiovascular surgery Heart surgery An operation for repairing structural defects of the cardiovascular system Examples CABG, repair of congenital heart defects, varicose veins, aortic aneurysms, ventricular remodeling, transmyocardial . Reasons to Purchase --Understand the key factors that will contribute to the success of the next generation of antithrombotics --Assess and beat the barriers to entry created by the lifecycle strategies of existing market players --Find out what market opportunities remain where developmental anticoagulants, antiplatelets and thrombolytics are unable to fulfill unmet needs For more information visit http://www.researchandmarkets.com/reports/c27837 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion